Accordingly, RAD51 inhibition sensitized chemoresistant breast cancer cells to doxorubicin and docetaxel [25] and increased the sensitivity of breast cancer cells to adriamycin and cisplatin [26]. The gene discussed is RAD51; the disease is breast cancer.